Advanced veterinary therapies attract increasing regulatory attention
Advanced therapeutics are becoming an increasingly important area of veterinary pharmaceutical development, particularly in companion-animal medicine.
Cell-based products, extracellular vesicles and veterinary oncology medicines represent three areas with significant research and commercial potential. South Korea taking the lead in advancing review guidance in these categories.
Why these regulatory categories matter
1. Veterinary cell therapies – Cell-based products require specialised manufacturing and quality controls. Regulatory assessment generally needs to address:
-
Cell identity and characterisation.
-
Purity and viability.
-
Manufacturing consistency.
-
Potency and biological activity.
-
Contamination control.
-
Product stability.
-
Clinical safety and efficacy.


